<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955343</url>
  </required_header>
  <id_info>
    <org_study_id>IRLC-1109</org_study_id>
    <nct_id>NCT01955343</nct_id>
  </id_info>
  <brief_title>Immune Response in Lung Cancer</brief_title>
  <acronym>IRLC</acronym>
  <official_title>Immune Response in Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <authority>Lithuania: Bioethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the importance of the immune cells localization
      (distribution) between malignant tumor islets and surrounding stroma and to investigate the
      associations between these immune cells as well as cytokines and clinicopathological and
      prognostic factors of non-small cell lung cancer (NSCLC) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>one year after enrolment to the study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lung cancer</arm_group_label>
    <description>Patients with histologically confirmed non small cell lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without lung cancer or other malignancies</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum and lung biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lithuanian residents who are investigated ant treated in Hospital of Lithuanian University
        of Health Sciences Kaunas Clinics Department of Pulmonology and Immunology  and Department
        of Heart, thoracic and vascular surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eastern Cooperative Oncology Group (ECOG) score of 0-1 Patients with histologically
        documented non-small cell lung cancer Control group - patients without non-small cell lung
        cancer Written (signed) Informed Consent to participate in the study

        Exclusion Criteria:

        Any other malignancies within 5 years Any unstable systemic disease (including active
        infections, significant cardiovascular disease) Prior chemotherapy or radiotherapy
        Autoimmune disease Nursing or pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius Zemaitis, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lithuanian University of Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marius Zemaitis, Assoc.Prof.</last_name>
    <phone>+37061256473</phone>
    <email>marius.zemaitis@kaunoklinikos.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jurgita Jackute, PhD</last_name>
    <phone>+37068216024</phone>
    <email>jjackute@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>LT 44307</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remigijus Zaliunas, Professor</last_name>
      <phone>+37037327200</phone>
      <email>rektoratas@lsmuni.lt</email>
    </contact>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Marius Zemaitis</investigator_full_name>
    <investigator_title>Assoc. Professor</investigator_title>
  </responsible_party>
  <keyword>Immune response</keyword>
  <keyword>Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
